Partial versus full agonists for opioid-mediated analgesia - Focus on fentanyl and buprenorphine

Acta Anaesthesiologica Belgica

Volumn 53, Issue 3, 2002, Pages 193-201

  Zuurmond, Wouter W ^a   Meert, T F ^b   Noorduin, H ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Buprenorphine; Clinical practice; Fentanyl; Full agonists; Partial agonists

Indexed keywords

BUPRENORPHINE; FENTANYL; FENTANYL DERIVATIVE; MORPHINE; MU OPIATE RECEPTOR AGONIST; OPIATE;

ANALGESIA; ANAPHYLAXIS; CONSTIPATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG TOLERABILITY; DYSPHORIA; EUPHORIA; HUMAN; MOLECULAR WEIGHT; NAUSEA; PHYSICAL CHEMISTRY; PRURITUS; RECEPTOR BINDING; RESPIRATION DEPRESSION; REVIEW; SEDATION; SOMNOLENCE; STATISTICAL SIGNIFICANCE; VASCULAR RESISTANCE; VOMITING;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; DRUG DELIVERY SYSTEMS; DRUG TOLERANCE; FENTANYL; HUMANS; PAIN; RECEPTORS, OPIOID, MU; SUBSTANCE-RELATED DISORDERS;

EID: 0036984389     PISSN: 00015164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Abram S. E., Mampilly G. A., Milosavljevic D., Assessment of the potency and intrinsic activity of systemic versus intrathecal opioids in rats, ANESTHESIOLOGY, 87, 127-134, 1997.
2. Ackerman W. E., Juneja M. M., Kaczorowski D. M., Colclough G. W., A comparison of the incidence of pruritus following epidural opioid administration in the parturient, CAN. J. ANAESTH., 36, 388-391, 1989.
3. Adriaensen H., Mattelaer B., Vanmeenen H., A long-term open, clinical and pharmacokinetic assessment of sublingual buprenorphine in patients suffering from chronic pain, ACTA ANAESTH. BELG., 36, 33-40, 1985.
4. Benedict P. E., Benedict M. B., Su T.P., Bolling S. F., Opiate drugs and delta-receptor-mediated myocardial protection, CIRCULATION, 100 (Suppl. 19), II357-360, 1999.
5. Boas R. A., Villiger J. W., Clinical actions of fentanyl and buprenorphine. The significance of receptor binding, BR. J. ANAESTH., 57, 192-196, 1985.
6. Bovill J. G., Which potent opioid? Important criteria for selection, DRUGS, 33, 520-530, 1987.
7. Bradley J. P., A comparison of morphine and buprenorphine for analgesia after abdominal surgery, ANAESTH. INTENSIVE CARE, 12, 303-310, 1984.
8. Brockway M. S., Noble D. W., Sharwood-Smith G. H., McClure J. H., Profound respiratory depression after extradural fentanyl, BR. J. ANAESTH., 64, 243-245, 1990.
9. Bryant R. M., Olley J. E., Tyers M. B., Antinociceptive actions of morphine and buprenorphine given intrathecally in the conscious rat, BR. J. PHARMACOL., 78, 659-663, 1983.
10. Bullingham R. E., McQuay H. J., Moore R. A., Clinical pharmacokinetics of narcotic agonist-antagonist drugs, CLIN. PHARMACOKINET., 8, 332-343, 1983.
11. Carl P., Crawford M. E., Madsen N. B., Ravlo O., Bach V., Larsen A. I., Pain relief after major abdominal surgery: a double-blind controlled comparison of sublingual buprenorphine, intramuscular buprenorphine, and intramuscular meperidine, ANEST. ANALG., 66, 142-146, 1987.
12. Castro J. de, Meynadier J., Zanz M., Drugs. In: Castro J. de, Meynadier J., Zenz M., eds. Regional Opioid Analgesia. Dordrecht: Klumer Academic Publishers, 131-209, 1991.
13. Chrubasik J., Vogel W., Trotschler H., Farthmann E. H., Continuous-plus-on -demand epidural infusion of buprenorphine versus morphine in postoperative treatment of pain. Postoperative epidural infusion of buprenorphine, ARZNEIMITTELFORSCHUNG, 37, 361-363, 1987.
14. Cohen S., Amar D., Pantuck C. B., Pantuck E. J., Weissman A. B, Adverse effects of epidural 0.03% bupivacaine during analgesia after cesarean section, ANESTH. ANALG., 75, 753-756, 1992a.
15. Cohen S., Amar D., Pantuck C. B., Pantuck E. J., Weissman A. M., Landa S., Singer N., Epidural patient-controlled analgesia after cesarean section: buprenorphine0.015% bupivacaine with epinephrine versus fentanyl0.015% bupivacaine with and without epinephrine, ANESTH. ANALG., 74, 226-230, 1992b.
16. Collin E., Poulain P., Gauvain-Piquard A., Petit G., PichardLeandri E., Is disease progression the major factor in morphine 'tolerance' in cancer pain treatment?, PAIN, 55, 319-326, 1993.
17. Colpaert F. C., Niemegeers C. J., Janssen P. A., Nociceptive stimulation prevents development of tolerance to narcotic analgesia, EUR. J. PHARMACOL., 49, 335-336, 1978.
18. Colpaert F. C., Can chronic pain be suppressed despite purported tolerance to narcotic analgesia?, LIFE SCI., 24, 1201-1209, 1979.
19. Cowan A., Doxey J. C., Harry E. J., The animal pharmacology of buprenorphine, an oripavine analgesic agent, BR. J. PHARMACOL., 60, 547-554, 1977a.
20. Cowan A., Lewis J. W., Macfarlane I. R., Agonist and antagonist properties of buprenorphine, a new antinociceptive agent, BR. J. PHARMACOL., 60, 537-545, 1977b.
21. Dirig D. M., Yaksh T. L., Differential right shifts in the dose-response curve for intrathecal morphine and sufentanil as a function of stimulus intensity, PAIN, 62 321-328, 1995.
22. Donner B., Zenz M., Strumpf M., Raber M., Long-term treatment of cancer pain with transdermal fentanyl, J. PAIN SYMPTOM MANAGE., 15, 168-175, 1998.
23. Dum J. E., Herz A., In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions, BR. J. PHARMACOL., 74, 627-633, 1981.
24. Duthie D. J., Nimmo W. S., Adverse effects of opioid analgesic drugs, BR. J. ANAESTH., 59, 61-77, 1987.
25. Emmett-Oglesby M. W., Shippenberg T. S., Herz A., Tolerance and cross-tolerance to the discriminative stimulus properties of fentanyl and morphine, J. PHARMACOL. EXP. THER., 245, 17-23, 1988.
26. Fischer G., Gombas W., Eder H., Jagsch R., Peternell A., Stuhlinger G., Pezawas L., Aschauer H. N., Kasper S., Buprenorphine versus methadone maintenance for the treatment of opioid dependence, ADDICTION, 94, 1337-1347, 1999.
27. Gal T. J, Naloxone reversal of buprenorphine-induced respiratory depression, CLIN. PHARMACOL. THER., 45, 66-71, 1989.
28. Grond S., Radbruch L., Lehmann K. A., Clinical pharmacokinetics of transdermal opioids:focus on transdermal fentanyl, CLIN. PHARMACOKINET., 38, 59-89, 2000.
29. Grond S., Zech D., Lehmann K. A., Radbruch L., Breitenbach H., Hertel D., Transdermal fentanyl in the long-term treatment of cancer pain: A prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region, PAIN, 69, 191-198, 1997.
30. Hambrook J. M., Rance M. J., The interaction of buprenorphine with the opiate receptor Lipophilicity as a determining factor in drug receptor kinetics. In: Kosterlitz H. W., ed. Opiates and Endogenous Opioid Peptides. Amsterdam: Elsevier/North Holland Biomedical Press, 295, 1976.
31. Hayashi H., Nishiuchi T., Tamura H., Takeda K., [Comparison of buprenorphine and fentanyl for postoperative pain relief by continuous epidural infusion], MASUI., 42, 1763-1768, 1993. Japanese.
32. Heel R. C., Brogden R. N., Speight T. M., Avery G. S., Buprenorphine: a review of its pharmacological properties and therapeutic efficacy, DRUGS, 17, 81-110, 1979.
33. Heyman J. S., Williams C. L., Burks T. F., Mosberg H. I., Porreca F., Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine, J. PHARMACOL. EXP. THER., 245, 238-243, 1988.
34. Hill C. S. Jr., The barriers to adequate pain management with opioid analgesics, SEMIN. ONCOL., 20 (2 Suppl. 1), 1-5, 1993.
35. Jasinski D. R., Human pharmacology of narcotic antagonists, BR. J. CLIN. PHARMACOL., 7 (Suppl 3), 287S-290S, 1979.
36. Johnson S. M., Duggan A. W., Dependence in the absence of tolerance to morphine, EUR. J. PHARMACOL., 97, 305-308, 1984.
37. Joranson D. E., Ryan K. M., Gilson A. M., Dahl J. L., Trends in medical use and abuse of opioid analgesics, JAMA, 283, 1710-1714, 2000.
38. Knape J. T, Early respiratory depression resistant to naloxone following epidural buprenorphine, ANESTHESIOLOGY, 64, 382-384, 1986.
39. Leander J. D., Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice, EUR. J. PHARMACOL., 151, 457-461, 1988.
40. Lehmann K. A., Zech D., Transdermal fentanyl: clinical pharmacology, J. PAIN SYMPTOM MANAGE., 7 (3 Suppl.), S8-16, 1992.
41. Levy J. H., Brister N. W., Shearin A., Ziegler J., Hug C. C. Jr., Adelson D. M., Walker B. F., Wheal and flare responses to opioids in humans, ANESTHESIOLOGY, 70, 756-760, 1989.
42. Marone G., Stellato C., Mastronardi P., Mazzarella B., Mechanisms of activation of human mast cells and basophils by general anesthetic drugs, ANN. FR. ANESTH. REANIM., 12, 116-125, 1993.
43. Martin W. R., Eades C. G., Thompson J. A., Huppler R. E., Gilbert P. E., The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog, J. PHARMACOL. EXP. THER., 197, 517-532, 1976.
44. Mather L. E., Clinical pharmacokinetics of fentanyl and its newer derivatives, CLIN. PHARMACOKINET., 8, 422-446, 1983.
45. Meert T. E, Pharmacological effects of epidural opioids, THER. TODAY, 8, 1-9, 1989.
46. Meert T. E, Pharmacotherapy of opioids: present and future developments, PHARM. WORLD SCI., 18, 1-15, 1996.
47. Muller H., Gerlach H., Gips H., Richter M., Borner U., Hempelmann G., [Intra- and postoperative interactions between the 2 opioids fentanyl and buprenorphine], ANAESTHETIST, 35, 219-225, 1986. German.
48. Negus S. S., Picker M. J., Dykstra L. A., Interactions between the discriminative stimulus effects of mu and kappa opioid agonists in the squirrel monkey, J. PHARMACOL. EXP. THER., 256, 149-158, 1991.
49. Ocana M., Del Pozo E., Barrios M., Baeyens J. M., Subgroups among mu-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs, BR. J. PHARMACOL., 114, 1296-1302, 1995.
50. Ohtani M., Kotaki H., Nishitateno K., Sawada Y., Iga T., Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine, J. PHARMACOL. EXP. THER., 281, 428-433, 1997.
51. Paix A., Coleman A., Lees J., Grigson J., Brooksbank M., Thorne D., Ashby M., Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management, PAIN, 63, 263-269, 1995.
52. Paronis C. A., Holtzman S. G., Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats, J. PHARMACOL. EXP. THER., 262, 1-9, 1992.
53. Payne R., Mathias S. D., Pasta D. J., Wanke L. A., Williams R., Mahmoud R., Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine, J. CLIN. ONCOL., 16, 1588-1593, 1998.
54. Portenoy R. K., Opioid therapy for chronic nonmalignant pain: a review of the critical issues, J. PAIN SYMPTOM MANAGE., 11, 203-217, 1996.
55. Portenoy R. K., Savage S. R., Clinical realities and economic considerations: special therapeutic issues in intrathecal therapy - tolerance and addiction, J. PAIN SYMPTOM MANAGE., 14(3 Suppl), S27-35, 1997.
56. Rahman A. F., Takahashi M., Kaneto H., Morphine dependence with or without tolerance in formalin-treated mice: further evidence for dissociation, JPN. J. PHARMACOL., 66, 277-280, 1994.
57. Rosow C. E., Moss J., Philbin D. M., Savarese J. J., Histamine release during morphine and fentanyl anesthesia, ANESTHESIOLOGY, 56, 93-96, 1982.
58. Saeki S., Yaksh T. L., Suppression of nociceptive responses by spinal mu opioid agonists: effects of stimulus intensity and agonist efficacy, ANESTH. ANALG., 77, 265-274, 1993.
59. Schug S. A., Merry A. F., Acland R. H., Treatment principles for the use of opioids in pain of nonmalignant origin, DRUGS, 42, 228-239, 1991.
60. Schmidt J. F., Chraemmer-Jorgensen B., Pedersen J. E., Risbo A., Postoperative pain relief with naloxone. Severe respiratory depression and pain after high dose buprenorphine, ANAESTHESIA, 40, 583-586, 1985.
61. Selley D. E., Sim L. J., Xiao R., Liu Q., Childers S. R., muOpioid receptor-simulated guanosine-5′-O-(gammathio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy, MOL. PHARMACOL., 51, 87-96, 1997.
62. Sittl R., Analgesic efficacy and safety of buprenorphine TTS in patients with chronic pain. Poster presented at the Third Congress of EFIC, Nice, France, September 2000.
63. Sloan P. A., Moulin D. E., Hays H., A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain, J. PAIN SYMPTOM MANAGE., 16, 102-111, 1998.
64. Smith M. A., Picker M. J., Tolerance and cross-tolerance to the rate-suppressing effects of opioids in butorphanol-treated rats: influence of maintenance dose and relative efficacy at the mu receptor, PSYCHOPHARMACOLOGY (BERL.), 140, 57-68, 1998.
65. Stellato C., Cirillo R., de Paulis A., Casolaro V., Patella V., Mastronardi P., Mazzarella B., Marone G., Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release, ANESTHESIOLOGY, 77, 932-940, 1992.
66. Stevens C. W., Yaksh T. L., Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion, J. PHARMACOL. EXP. THER., 250, 1-8, 1989.
67. Stoeckel H., Schüttler J., Magnussen H., Hengstmann J. H., Plasma fentanyl concentrations and the occurrence of respiratory depression in volunteers, BR. J. ANAESTH., 54, 1087-1095, 1982.
68. Thorn S. E., Rawal N., Wennhager M., Prolonged respiratory depression caused by sublingual buprenorphine, LANCET, 1, 179-180, 1988.
69. Tigerstedt I., Tammisto T., Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain, ACTA ANAESTHESIOL. SCAND., 24, 462-468, 1980.
70. van den Berg A. A., Honjol N. M., Prabhu N. V., Datta S., Rozario C. J., Muraleedaran R., Savva D., Analgesics and ENT surgery. A clinical comparison of the intraoperative, recovery and postoperative effects of buprenorphine, diclofenac, fentanyl, morphine, nalbuphine, pethidine and placebo given intravenously with induction of anaesthesia, BR. J. CLIN. PHARMACOL., 38, 533-543, 1994.
71. Villiger J. W., Ray L. J., Taylor K. M., Characteristics of [3H]fentanyl binding to the opiate receptor, NEUROPHARMACOLOGY, 22, 447-452, 1983.
72. Villiger J. W., Binding of buprenorphine to opiate receptors. Regulation by guanyl nucleotides and metal ions, NEUROPHARMACOLOGY, 23, 373-375, 1984.
73. Walsh S. L., Preston K. L., Stitzer M. L., Cone E. J., Bigelow G. E., Clinical pharmacology of buprenorphine: ceiling effects at high doses, CLIN. PHARMACOL. THER., 55, 569-580, 1994.
74. Wang C. Y., Respiratory depression after extradural fentanyl, BR. J. ANAESTH., 69, 544, 1992.
75. Wang C., Chakrabarti M. K., Whitwam J. G., Lack of a ceiling effect for intrathecal buprenorphine on C fibre mediated somatosympathetic reflexes, BR. J. ANAESTH., 71, 528-533, 1993.
76. nd edition) Geneva, Switzerland, 1996.
77. Zaki P. A., Keith D. E. Jr., Brine G. A., Carroll F. I., Evans C. J., Ligand-induced changes in surface muopioid receptor number: relationship to G protein activation?, J. PHARMACOL. EXP. THER., 292, 1127-1134, 2000.